HighMark Wealth Management LLC Raises Position in Evolent Health, Inc. (NYSE:EVH)

HighMark Wealth Management LLC raised its stake in Evolent Health, Inc. (NYSE:EVH) by 57.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,275 shares of the technology company’s stock after purchasing an additional 11,800 shares during the quarter. HighMark Wealth Management LLC’s holdings in Evolent Health were worth $363,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Creative Planning boosted its holdings in Evolent Health by 139.1% in the third quarter. Creative Planning now owns 43,262 shares of the technology company’s stock valued at $1,223,000 after purchasing an additional 25,171 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in Evolent Health during the 3rd quarter valued at $1,421,000. Values First Advisors Inc. grew its position in Evolent Health by 21.0% in the 3rd quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company’s stock valued at $909,000 after buying an additional 5,583 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Evolent Health by 180.3% in the third quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock valued at $186,000 after buying an additional 4,232 shares during the period. Finally, Harbor Capital Advisors Inc. grew its position in Evolent Health by 140.0% in the third quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock worth $11,946,000 after buying an additional 246,400 shares during the last quarter.

Wall Street Analyst Weigh In

EVH has been the subject of a number of research analyst reports. Royal Bank of Canada reduced their price target on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Evolent Health in a report on Wednesday, February 12th. Barclays reduced their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. UBS Group cut their price target on Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. Finally, JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a research note on Friday. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.92.

Evolent Health Stock Up 1.0 %

EVH opened at $10.07 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The business’s fifty day simple moving average is $10.84 and its 200 day simple moving average is $19.13. Evolent Health, Inc. has a 52 week low of $9.45 and a 52 week high of $35.00. The stock has a market cap of $1.17 billion, a PE ratio of -11.06 and a beta of 1.45.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.